抗高血压药物广告的发展趋势,1985-1996年
T J Wang1, J C Ausiello, R S Stafford
1Institute for Health Policy and General Medicine Division, Massachusetts General Hospital, Boston, MA 02114, USA.
Circulation
|April 20, 1999
概括
药品广告显著增加了通道阻断剂 (CCB),反映了它们在高血压治疗中的兴起. 这表明营销影响了医生的处方,可能会取代其他疗法.
科学领域:
- 心脏病学 心脏病学
- 药品营销 药品营销 药品营销
- 医学经济学 医学经济学
背景情况:
- 高血压治疗趋势显示,通道阻断剂 (CCB) 和ACE抑制剂的使用增加,在过去十年中,β阻断剂和利尿剂的使用减少.
- 药品营销被怀疑会影响这些处方模式,但对抗高血压药物广告缺乏客观分析.
研究的目的:
- 对抗高血压药物的广告趋势进行客观分析.
- 调查药品广告与医生为高血压治疗开处方模式之间的关联.
主要方法:
- 从1985年到1996年,对"新英格兰医学杂志" (New England Journal of Medicine) 的广告内容进行了审查.
- 通过测量专门用于特定药物类别的广告页面比例来量化药物推广强度.
- 使用 chi2 测试进行趋势统计分析,以评估随时间变化的变化.
主要成果:
- 对CCB的广告从1985年的4.6%急剧增加到1996年的26.9% (P<0.0001).
- 贝塔抑制剂和利尿剂的广告在1996年降至0% (P<0.0001).
- 尽管药品广告页面总体下降,但CCB广告几乎增加了四倍.
结论:
- CCB推广的增加与医生对这些药物的处方增加有关.
- 增加的广告和处方模式之间存在潜在的关联,这可能解释了CCBs取代了其他高血压治疗方法.
相关概念视频
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

